Drugs called GLP‑1 agonists, like Ozempic, Wegovy and Rybelsus, are famous for helping people lose weight and control blood sugar. Scientists have now found another possible good side‑effect. A recent trial suggests that the main ingredient, semaglutide, might slow some of the body’s aging signals.
What the Study Found
The research was published in Nature Communications. It is the first human trial that used a randomised, placebo‑controlled design to look at aging markers in people with HIV.
Researchers used data from an earlier trial with 108 adults who had extra belly fat because of HIV. About half received a weekly shot of semaglutide, while the rest got a fake injection.
To measure aging, the team used “epigenetic clocks.” These clocks read tiny chemical tags on DNA that tell how old a cell seems to be. When the tags change, they can show if the body is aging faster or slower.
Compared with the fake‑injection group, the semaglutide group showed:
- Slower aging on several clocks that look at inflammation and the health of blood, brain, heart, kidneys, liver and metabolism.
- A 9 % slower aging rate on the DunedinPACE clock.
- Big drops in aging signals linked to disease risk on the PCGrimAge clock.
How Might GLP‑1 Drugs Influence Aging?
Scientists think semaglutide works in a few ways. It cuts down inflammation and improves how the body handles sugar and fats. This can lower the constant immune activity that speeds up aging, especially in people with HIV.
The drug also reduces visceral and ectopic fat – the hidden fat around organs and in unusual places. Less of this harmful fat means fewer inflammatory messages that push aging forward.
“New data hint that GLP‑1 drugs may even re‑program some cells,” said one of the investigators.
Could the Results Apply to Everyone?
Although the trial focused on people with HIV‑related belly fat, the scientists believe the findings could matter to the wider population. Many of the aging pathways they studied are the same for everyone.
“We use the HIV group to spot changes early. If a drug works here, it might help the rest of us too,” the researcher explained.
Healthspan is the time we stay healthy and free from serious age‑related illnesses, not just how long we live.
Another Study Shows Similar Results
A smaller pilot study in npj Aging looked at semaglutide for 24 weeks in people with HIV and fatty liver disease. It found:
- 42 % of participants had slower aging on the DunedinPACE clock, and they lost more liver fat.
- 34 % showed slower aging linked to overall death risk on the PCGrimAge clock.
- Almost half had longer telomeres – the protective caps on DNA – and walked faster after treatment.
What the Scientists Say Next
The team warns that semaglutide is not a magic anti‑aging pill. It does not reverse age, but it may slow some of the processes that make us age.
Future work will need bigger studies to see how long the benefits last, which patients gain the most, and how the drug works with good habits like healthy eating, exercise and sleep.
One goal is to create personal “aging dashboards” that use epigenetic clocks to help doctors track biological age and tailor treatments.